Impax Wins Round in Battle Over Claritin-D
HAYWARD — Impax Laboratories Inc. on Wednesday won tentative regulatory approval for a generic version of Schering-Plough Corp.’s allergy drug Claritin-D, sending its shares up 3.8%.
Final Food and Drug Administration approval depends on the outcome of a patent lawsuit Schering-Plough brought against Impax, the expiration of a stay preventing approval of a generic for 30 months when a patent-infringement suit is filed and the expiration of any generic marketing exclusivity, Impax said.
Rival Andrx Corp. was the first generic-drug maker to seek approval for the 24-hour extended release form of the drug, which would give that company a six-month head start in the market before other generic versions were allowed under FDA rules, said Barry Edwards, co-chief executive of Impax.
Claritin-D had annual U.S. sales of about $539 million for the 12 months ended March 31.
Impax, which had sales of $6.6 million last year, is seeking FDA permission to sell generic copies of 15 brand-name products, including Aventis’ allergy medicine Allegra.
Schering-Plough’s lawsuit says Impax’s November 2000 filing with the FDA violated two patents covering Claritin. Those patents don’t expire until 2004 and 2014, Schering-Plough alleged in the lawsuit.
Shares of Impax, based in Hayward, Calif., rose 30 cents to $8.20 on Nasdaq. The shares have lost more than 30% of their value in the last 12 months.
Shares of Schering-Plough fell 5 cents to $26.50 on the New York Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
